

**MISSISSIPPI DIVISION OF MEDICAID
DRUG UTILIZATION REVIEW (DUR) BOARD
MINUTES OF THE DECEMBER 6, 2018 MEETING**

DUR Board Members:	Mar 2018	May 2018	Sep 2018	Dec 2018
Lauren Bloodworth, PharmD	NA	NA	✓	✓
Beverly Bryant, MD	NA	NA	✓	✓
Rhonda Dunaway, RPh	✓	✓	✓	✓
Tanya Fitts, MD	NA	NA	✓	✓
Juanice Glaze, RPh	✓	✓	✓	✓
Alice Messer, DNP, FNP-BC	✓	✓		
Ray Montalvo, MD	✓	✓		✓
Holly Moore, PharmD	✓		✓	✓
Janet Ricks, DO	✓		✓	✓
Dennis Smith, RPh	✓	✓	✓	✓
James Taylor, PharmD (Chair)	✓	✓	✓	✓
Veda Vedanarayanan, MD	NA	NA		✓
TOTAL PRESENT	9*	8**	9	11

** Only 11 members were active due to resignation resulting from move and replacements not yet approved by Governor.*

***Only 10 members were active due to resignations resulting from move and replacements not yet approved by Governor.*

Also Present:

Division of Medicaid (DOM) Staff:

Terri Kirby, RPh, CPM, Pharmacy Director; Cindy Noble, PharmD, MPH, DUR Coordinator; Gail McCorkle, RPh, Clinical Pharmacist; Chris Yount, MA, PMP, Staff Officer – Pharmacy; Carlos Latorre, MD, Medical Director; Sue Reno, RN, Program Integrity

University of Mississippi School of Pharmacy - MS-DUR Staff:

Ben Banahan, PhD, MS-DUR Project Director; Eric Pittman, PharmD, MS-DUR Clinical Director

Conduent Staff:

Lew Anne Snow, RN, BSN, Pharmacy Services Sr. Analyst, Mississippi Medicaid Project

Change Healthcare Staff:

Shannon Hardwick, RPh, CPC Pharmacist; Paige Clayton, PharmD, On-Site Clinical Pharmacist; Cheryl Rogers, PharmD, Mississippi PA Pharmacist

Coordinated Care Organization Staff:

Heather Odem, PharmD, United Healthcare Community & State, Director of Pharmacy- Mississippi; Jenni Grantham, PharmD, Director of Pharmacy, Magnolia Health; Mike Todaro, PharmD, Vice President, Pharmacy Operations, Magnolia Health; Trina Stewart, PharmD, Pharmacy Manager, Molina Healthcare; Joseph Vazhappilly, PharmD, MBA, Associate Vice President, Pharmacy Services, Molina Healthcare

Visitors:

Phil Hecht, Abbvie; Dustin Prisock, Kite; Tim Hambacher, Otsuka; Brian Berhow, Sunovion; Kim Clark, Viiv; Jason Swartz, Otsuka; Eric Marchant, Amgen; Evelyn Johnson, Capital Resources

Call to Order:

Dr. Taylor, Chair, called the meeting to order at 2:03pm and welcomed everyone. Dr. Taylor officially welcomed new Board member Dr. Vedanarayanan.

Old Business:

Mr. Smith moved to approve the minutes from the September 2019 DUR Board Meeting, seconded by Dr. Montalvo and unanimously approved by the DUR Board.

Resource Utilization Review:

Dr. Pittman informed the Board that encounter data for one of the CCOs was incomplete for the reporting period. Antipsychotics have moved up in rank in amount paid due their inclusion in the Clinician Administered Drugs and Implantable Drug System Devices (CADD) list allowing injectable antipsychotics to be billed through point of sale (POS). This increase does not reflect an increase in utilization rather a change in area of reimbursement. No other major items noted in the reports.

Pharmacy Program Update:

Ms. Kirby informed the board about Medicaid's EASE Initiative, a bundle of programmatic changes aimed at bolstering Medicaid beneficiaries' access to needed services in the most appropriate setting. As part of the first phase, DOM will increase the physician visit limit for beneficiaries from 12 to 16 visits per year. She also informed the board Dr. Carlos Latorre was recently hired as the new Medical Director at DOM. He will be the first full-time Medical Director. Due to his full-time position, Dr. Noble asked that the Board consider amending the DUR Board Bylaws to include the Medical Director as a non-voting member.

Dr. Montalvo made a motion to revise the bylaws to include the Medical Director as a non-voting member, seconded by Dr. Bryant, and unanimously approved by the DUR Board.

Dr. Latorre was officially welcomed to the DUR Board.

Update on Action Items from Previous Board Meetings

Dr. Pittman reviewed educational mailing statistics for mailings conducted since the last board meeting.

Stimulant Edit Implementation

Dr. Taylor asked for feedback from the Board on the diagnosis edit requirement for stimulants. DOM reported some difficulties experienced during implementation, while Board members also expressed some of their experiences.

NEW BUSINESS***Influenza Vaccination and Treatment Overview***

Dr. Pittman provided an overview and reviewed trends related to the 2017-2018 flu season. Even though Mississippi's rate of flu cases in the 2017-2018 flu season was higher than the national and regional averages, Mississippi's vaccination rate was higher nationally and regionally. Dr. Pittman also

reviewed prophylactic and treatment options for the flu virus. Prescribing patterns in Mississippi Medicaid during the 2017-2018 flu season were detailed. Noting the severity of the 2017-2018 flu season, Board members asked MS-DUR to conduct further analysis examining concomitant antibiotic use with antiviral therapy, age-specific analyses, and trends in high-risk populations. Additionally Board members requested MS-DUR assess days supply of antiviral therapy to determine what percentages were prescribed for prophylaxis and treatment of flu. The Board also requested MS-DUR annually present an overview of the prior year's flu season at the fall Board meeting each year.

COPD Treatment Patterns and GOLD Guidelines

Dr. Pittman reviewed information on COPD and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. MS-DUR identified Medicaid beneficiaries with a diagnosis of COPD who experienced an exacerbation event resulting in an emergency department visit or hospital admission. Prescribing patterns after each exacerbation were assessed to determine alignment with the GOLD guidelines. A robust Board discussion was held regarding the data presented focusing on barriers and opportunities for improving adherence to the GOLD guidelines. MS-DUR recommendations included the following:

1. DOM and MS-DUR should undertake a provider educational initiative to promote greater adherence to the GOLD guidelines. As part of the educational initiatives, the Board advocated for the inclusion of provider recommendations for immunization and smoking cessation in COPD patients.
2. If possible, DOM and the CCOs should implement patient management programs to improve medication adherence and help assure appropriate treatment regimens among COPD patients following an exacerbation event.
3. CCOs are invited to present at the next DUR meeting their initiatives and related outcomes on improving treatment regimens for COPD beneficiaries.

Mr. Smith made a motion to approve the MS-DUR recommendations, seconded by Dr. Bryant, and unanimously approved by the DUR Board.

Multiple Antipsychotic Medication Prescribing Trends in Children and Adults

Dr. Banahan provided an overview of trends in the prescribing of multiple antipsychotic medications in children and adults. Background pertaining to previous DUR recommendations and educational initiatives relating to the use of multiple antipsychotic medications in children was also presented. Following a robust discussion, the following MS-DUR recommendations were presented:

1. Examine prior authorization approvals in the previous 12 months to determine rationales cited for concurrent use of multiple antipsychotic medications.
2. Expand prior authorization form to also include the adult population.

Dr. Montalvo made a motion to approve the MS-DUR recommendations, seconded by Ms. Dunaway, and unanimously approved by the DUR Board.

FDA Drug Safety Updates

Dr. Pittman presented FDA drug safety communications from August 2018 – November 2018

Next Meeting Information:

Dr. Taylor asked for feedback on proposed dates for next year. The proposed 2019 dates, March 7, May 23, September 19 and December 5, were accepted by the Board. Dr. Taylor announced that the next

meeting of the DUR Board will take place on March 7, 2019 and made note that start time will change to 1:00 pm in order to better accommodate those who drive long distances for meetings.

The meeting adjourned at 4:03 pm.

Submitted,

Eric Pittman, PharmD
Evidence-Based DUR Initiative, MS-DUR

Meeting Location: Woolfolk Building, 501 North West Street, Conference Room 145 Jackson, MS 39201

Contact Information: Pharmacy Bureau:

Chris Yount, 601-359-5253; Christopher.yount@medicaid.ms.gov, or
Jessica Tyson, 601-359-5253; jessica.Tyson@medicaid.ms.gov

Notice details:

State Agency: MS Division of Medicaid

Public Body: Drug Utilization Board (DUR) Meeting

Subject: Quarterly Meeting

Date and Time: May 31, 2018 at 2PM; Sept. 20, 2018 at 2PM; Dec. 6, 2018 at 2PM.

Description: The Mississippi Division of Medicaid's Drug Utilization Review (DUR) Board is a quality assurance body which seeks to assure appropriate drug therapy to include optimal beneficiary outcomes and appropriate education for physicians, pharmacists, and the beneficiary. The Drug Utilization Review (DUR) Board is composed of twelve participating physicians and pharmacists who are active MS Medicaid providers and in good standing with their representative organizations.

The Board reviews utilization of drug therapy and evaluates the long-term success of the treatments.

The Drug Utilization Review (DUR) Board meets quarterly.